

Product Datasheet

Paltusotine

Catalog No. **BP-01984** · CAS **2172870-89-0** · Form **free base** · Physical state **solid** · Color **white to yellow** · Version **1.0** ·
Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Amyloid-β	Research area Neurological Disease
----------------------------	--

Molecular formula **C₂₇H₂₂F₂N₄O**

Molecular weight **456.4866**

STRUCTURE



DESCRIPTION

Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.

BIOLOGICAL ACTIVITY

ALZ-801 (oral administration; 172?mg/kg; single dose) exhibits mean AUCt values of 58,758 and? 5841 ng/ml.h in plasma and brain, respectively. The ALZ-801: Tramiprosate ratio in plasma and brain is 1.8 and 3.1, respectively in male CD-1 mice

SOLUBILITY

Soluble in H₂O : 30 mg/mL

REFERENCES

- [1]. Murray B. Gordon, et al. Identification of a dose range for once daily oral paltusotine in patients with acromegaly that maintains IGF-1 levels when switching from long-acting somatostatin receptor ligand therapy. Endocrine Abstracts (2021) 73 OC15.4.
- [2]. Rosa Luo, et al. Pharmacokinetics and Safety of an Improved Oral Formulation of Paltusotine, a Selective, Non-Peptide Somatostatin Receptor 2 (SST2) Agonist for the Treatment of Acromegaly. Journal of the Endocrine Society, Volume 5, Issue Supplement_1, A